PROSPECTIVE MULTICENTER STUDY ON THE CLINICAL UTILITY OF CA-72.4 IN POSTMENOPAUSAL PATIENTS WITH PELVIC MASS

  • Authors:
    • T MAGGINO
    • A GADDUCCI
    • V DADDARIO
    • S PECORELLI
    • A LISSONI
    • M STELLA
    • C ROMAGNOLO
    • M FERDEGHINI
    • S ZUCCA
    • D TRIO
    • S TROVO
  • View Affiliations

  • Published online on: November 1, 1995     https://doi.org/10.3892/or.2.6.1069
  • Pages: 1069-1074
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The study objective was to evaluate the sensitivity and specificity as well as the positive predictive value and negative predictive value of CA 72.4 and CA 125 determination, separately and in combination, for diagnosing ovarian tumors in post-menopausal women with pelvic mass. The 299 patients recruited in this study underwent gynecological examination, plasma determination of CA 72.4 and CA 125, and laparotomy with histological definition of pelvic mass. CA 72.4 assay values were under 3.9 U/ml in 194 cases (70.8%); values ranged from 3.9 to 4.5 U/ml in 7 cases (2.5%) and were greater than 4.5 U/ml in 73 cases (26.6%). CA 72.4 assay was positive (>4.5 U/ml) in 56 cases (57.1%) of malignant ovarian pathology, in 4 cases (25%) of malignant extra-ovarian pathology as well as in 9 cases (7.1%) of benign ovarian pathology and in 4 cases (11.8%) of benign extra-ovarian pathology. With a cut-off at 3.9 U/ml, CA 72.4 showed a specificity of 91.3% and a sensitivity of 62.2%, whereas with a cut-off at 4.5 U/ml specificity was 92.9% and sensitivity 57.1%. Results of CA 125 assay for diagnosing a pelvic neoplasia (ovarian or extra-ovarian), showed a specificity of 85.3% and sensitivity of 68.8%. The agreement of the two markers (CA 125 and CA 72.4) as negative or positive shows a specificity of 77% and a sensitivity of 84.7% for ovarian cancer and a specificity of 73.5% and sensitivity of 75% for the diagnosis of pelvic neoplasias.

Related Articles

Journal Cover

November 1995
Volume 2 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
MAGGINO T, GADDUCCI A, DADDARIO V, PECORELLI S, LISSONI A, STELLA M, ROMAGNOLO C, FERDEGHINI M, ZUCCA S, TRIO D, TRIO D, et al: PROSPECTIVE MULTICENTER STUDY ON THE CLINICAL UTILITY OF CA-72.4 IN POSTMENOPAUSAL PATIENTS WITH PELVIC MASS. Oncol Rep 2: 1069-1074, 1995
APA
MAGGINO, T., GADDUCCI, A., DADDARIO, V., PECORELLI, S., LISSONI, A., STELLA, M. ... TROVO, S. (1995). PROSPECTIVE MULTICENTER STUDY ON THE CLINICAL UTILITY OF CA-72.4 IN POSTMENOPAUSAL PATIENTS WITH PELVIC MASS. Oncology Reports, 2, 1069-1074. https://doi.org/10.3892/or.2.6.1069
MLA
MAGGINO, T., GADDUCCI, A., DADDARIO, V., PECORELLI, S., LISSONI, A., STELLA, M., ROMAGNOLO, C., FERDEGHINI, M., ZUCCA, S., TRIO, D., TROVO, S."PROSPECTIVE MULTICENTER STUDY ON THE CLINICAL UTILITY OF CA-72.4 IN POSTMENOPAUSAL PATIENTS WITH PELVIC MASS". Oncology Reports 2.6 (1995): 1069-1074.
Chicago
MAGGINO, T., GADDUCCI, A., DADDARIO, V., PECORELLI, S., LISSONI, A., STELLA, M., ROMAGNOLO, C., FERDEGHINI, M., ZUCCA, S., TRIO, D., TROVO, S."PROSPECTIVE MULTICENTER STUDY ON THE CLINICAL UTILITY OF CA-72.4 IN POSTMENOPAUSAL PATIENTS WITH PELVIC MASS". Oncology Reports 2, no. 6 (1995): 1069-1074. https://doi.org/10.3892/or.2.6.1069